Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG br0131

Neuro-Oncology

Volumn 11, Issue 2, 2009, Pages 167-175

  Vogelbaum, Michael A ^a   Berkey, Brian ^b   Peereboom, David ^a   Macdonald, David ^c   Giannini, Caterina ^d   Suh, John H ^b   Jenkins, Robert ^d   Herman, James ^e   Brown, Paul ^d   Blumenthal, Deborah T ^f   Biggs, Christopher ^g   Schultz, Christopher ^h   Mehta, Minesh ⁱ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c LONDON REGIONAL CANCER PROGRAM   (Canada)

^d MAYO CLINIC   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g Arizona Oncology Services   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DOLASETRON MESILATE; GRANISETRON; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PENTAMIDINE; TEMOZOLOMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTHRALGIA; ARTICLE; BLEEDING; BLURRED VISION; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HEADACHE; HEARING DISORDER; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFECTION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; LYMPHATIC SYSTEM DISEASE; MALE; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OLIGODENDROGLIOMA; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROTEIN METHYLATION; SECOND CANCER; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SPEECH DISORDER; THROMBOSIS; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; COMBINED MODALITY THERAPY; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE FRACTIONATION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 65949101643     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-073     Document Type: Article

References (26)

1. Mork SJ, Lindegaard KF, Halvorsen TB, et al. Oligodendroglioma: inci- dence and biological behavior in a defined population. J Neurosurg. 1985;63:881-889.
2. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for ana- plastic oligodendroglioma; National Cancer Institute of Canada Clini- cal Trials Group. J Clin Oncol. 1994;12:2013-2021.
3. Kim L, Hochberg FH, Thornton AF, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastro- cytomas. J Neurosurg. 1996;85:602-607.
4. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
5. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of ana- plastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-845.
6. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861.
7. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 2000;48:825-830.
8. Smith JS, Perry A, Borell TJ, et al. lterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
9. Chahlavi A, Kanner A, Peereboom D, et al. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol. 2003;61:267-273.
10. Thiessen B, Maguire JA, McNeil K, et al. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: rela- tionship to outcome and chemosensitivity. J Neurooncol. 2003;64: 271-278.
11. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714.
12. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procar- bazine, lomustine and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendro- gliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715.
13. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre- clinical development and clinical trials. Cancer Treat Rev. 1997;23: 35-61.
14. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozo- lomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367.
15. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolo- mide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
16. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2:552-560.
17. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozo- lomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001;19: 2449-2455.
18. van den Bent MJ, Keime-Guibert F, Brandes AA, et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology. 2001; 57:340-342.
19. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus con- comitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
20. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of malignant glioma. J Clin Oncol. 1990;8:1277-1280.
21. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18:4144-4152.
22. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001;61:4689-4692.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958; 53:457-481.
24. Mantel, N. Evaluation of survival data and two new rank order sta- tistics arising in its consideration. Cancer Chemotherapy Reports. 1966;50:163-170.
25. van den Bent MJ, Taphoorn MJB, Brandes AA, et al. Phase II study of first line chemotherapy with temozolomide in recurrent oligoden- droglial tumors: the European Organization for the Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003;21:2525-2528.
26. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment rec- ommendations for anaplastic oligodendroglioma. Neuro-Oncol. 2007;9:314-318.